吡格列酮联合辛伐他汀治疗混合性高脂血症的临床分析  

Clinical analysis of pioglitazone combined with simvastatin in the treatment of mixed hyperlipidemia

作　　者：苏强 伦志勇 梁燕芳 刘斌[2] 吴同果[3] 

机构地区：[1]广东省东莞市望牛墩镇社区卫生服务中心,广东东莞523200 [2]南方医科大学珠江医院急诊科,广东广州510280 [3]广州市红十字会医院(暨南大学医学院第四附属医院),广东广州510220

出　　处：《中国医药科学》2016年第24期35-37,103,共4页China Medicine And Pharmacy

摘　　要：目的探讨吡格列酮（PIO）联合辛伐他汀治疗混合性高脂血症的临床疗效与安全性。方法将146例混合性高脂血症患者按照数字表法随机分为两组,对照组73例给予辛伐他汀治疗,观察组73例在对照组基础上加用吡格列酮治疗,8周为一个疗程,比较两组的临床疗效。结果治疗12周后,观察组总有效率为94.52%高于对照组80.82%,差异有统计学意义（χ2=6.3368,P〈0.05）,观察组的TC、TG、LDL-C与3项达标均高于对照组,差异有统计学意义（χ2=14.7475、8.5568、15.3361、8.4304,P〈0.05）,两组治疗12周后TC、TG、HDL-C、LDL-C血脂参数变化水平与治疗前比较,两组血清TC、TG、LDL-C水平降低,差异有统计学意义（P〈0.05）,而血清HDL-C水平不同程度增高,观察组优于对照组,差异有统计学意义（P〈0.05）。结论吡格列酮联合辛伐他汀治疗混合性高脂血症具有优势互补的作用,能够显著地改善血脂变化,疗效显著,安全可靠,是较为理想的搭配药物。Objective To investigate the clinical efficacy and safety of pioglitazone（PIO） combined with simvastatin in the treatment of mixed hyperlipidemia. Methods 146 cases of patients with mixed hyperlipidemia were randomly divided into two groups according to the digital table method.73 cases in the control group were treated with simvastatin. 73 cases in the observation group were treated with pioglitazone on the basis of the control group. And the clinical efficacy of the two groups was compared. Results After 12 weeks of treatment, the total effective rate of the observation group was 94.52%, which was significantly higher than that of control group with 80.82%（χ2=6.3368, P 〈 0.05）.The levels of TC,TG and LDL-C in observation group were significantly higher than those in control group（χ2=14.7475, 8.5568, 15.3361, 8.4304,P 〈 0.05）. After 12 weekes of treatment,on the changes of TC,TG,HDL-C,LDL-C blood lipid parameters, compared with before the treatment, the serum TC,TG and LDL-C levels were significantly lower（P 〈 0.05）,while serum HDL-C levels were significantly higher, and the observation group was significantly better than the control group（P 〈 0.05）. Conclusion Pioglitazone combined with simvastatin in treatment of hyperlipidemia has the advantage of complementary effect. It can significantly improve blood lipid changes. The effect is significant, safe and reliable, and it is the ideal collocation of drugs.

关 键 词：混合性高脂血症 辛伐他汀 吡格列酮 

分 类 号：R543.3[医药卫生—心血管疾病]